Trials / Completed
CompletedNCT01435928
PEARL Schizophrenia Maintenance
A Double-Blind, Placebo-Controlled, Randomized Withdrawal Study Of Lurasidone For The Maintenance Treatment Of Subjects With Schizophrenia
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 676 (actual)
- Sponsor
- Sumitomo Pharma America, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
Lurasidone HCI is a compound that is FDA-approved for the treatment of schizophrenia. This clinical study is designed to test the hypothesis that Lurasidone is effective in the long term maintenance treatment of schizophrenia.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Lurasidone | Lurasidone 40 and 80 mg, once daily in the evening with a meal or 30 minutes after eating |
| DRUG | Matching Placebo | Matching placebo once daily in the evening with a meal or 30 minutes after eating |
Timeline
- Start date
- 2011-09-01
- Primary completion
- 2013-08-01
- Completion
- 2013-08-01
- First posted
- 2011-09-19
- Last updated
- 2016-04-08
- Results posted
- 2014-09-25
Locations
75 sites across 7 countries: United States, France, Italy, Russia, Serbia, Slovakia, South Africa
Source: ClinicalTrials.gov record NCT01435928. Inclusion in this directory is not an endorsement.